ArcticDx

ArcticDx has developed and commercialized genetic tests such as Macula Risk® and Vita Risk to identify patients at high risk of progression to advanced AMD. These tests help guide personalized treatment decisions regarding eye vitamin supplementation. Their Vita Risk test received U.S. Medicare approval in 2017.\n\nClinical results show that certain genotypes may be harmed by standard zinc-based supplements used in AMD management; thus, genetic testing can improve outcomes by personalizing therapy.\n\nThe company also develops products targeting Alzheimer’s disease but details on clinical results for this indication are not provided in public sources.\n\nTheir diagnostic tests are available commercially in North America and globally through certified laboratories.